Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO) (HB038016)

Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHB038016
Descripción
Brentuximab (HB038016) is a research-grade recombinant antibody targeting CD30L. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huéspedChimeric
ClonalidadMonoclonal
IsotipoIgG1-kappa
Sistema de expresión Mammalian cells
Aplicaciones probadas FCM
Objetivo CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Nivel de endotoxinas < 10 EU/mg
Pureza >95% purity as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P28908
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosSGN-35, cAC10-Val-Cit-MMAE, 914088-09-8, 2088770-90-3
Fondo

Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris).

1. Smith, CA. et al. (1993) Cell 73, 1349-60. PMID: 8391931
2. Aizawa, S. et al. (1997) The Journal of biological chemistry 272, 2042-5. PMID: 8999898
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Imágenes
  • Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)

    Bioactivity

    SEC-HPLC detection for Research Grade Brentuximab.

  • Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Brentuximab.

  • Anti-Human CD30/TNFRSF8 Reference Antibody (Brentuximab, RUO)

    Flow cytometry

    Flow-cytometry using APC anti-human TNFRSF8 antibody. Jurkat cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human TNFRSF8 monoclonal antibody (Catalog HB038016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores